Haloperidol Decanoat Richter

Haloperidol Decanoat Richter is a prescription intramuscular injection containing the active ingredient haloperidol decanoate, a long‑acting butyrophenone antipsychotic. It is marketed in the European Union and is classified under ATC code N05AD01. The formulation delivers haloperidol in a depot form, allowing sustained plasma concentrations after a single injection. It is intended for use under medical supervision in patients requiring antipsychotic therapy and long‑term management of schizophrenia.

Haloperidol Decanoat Richter is indicated for several psychiatric conditions where sustained antipsychotic coverage is desired, particularly when adherence to daily oral medication is challenging.

- Schizophrenia, including maintenance therapy after stabilization. - Acute psychotic episodes when oral therapy is not feasible. - Schizoaffective disorder requiring long‑acting treatment. - Adjunctive therapy in patients with treatment‑resistant psychosis. - Prevention of relapse in patients who have responded to oral haloperidol. - Use in combination with other antipsychotics under specialist supervision when monotherapy is insufficient.

Side‑effect profiles for haloperidol decanoate reflect its dopamine‑blocking activity and can range from mild, frequently observed reactions to rare but potentially life‑threatening events. Patients and clinicians should be aware of both common and serious adverse effects when initiating or continuing therapy.

Common: - Extrapyramidal symptoms such as tremor, rigidity, or akathisia - Sedation, drowsiness, or fatigue - Dry mouth and reduced salivation - Constipation or gastrointestinal slowing

Serious: - Neuroleptic malignant syndrome, a medical emergency - Tardive dyskinesia, potentially irreversible movement disorder - QT‑interval prolongation with risk of cardiac arrhythmia - Severe hypotension or syncope, especially after injection

Haloperidol Decanoat Richter requires careful assessment before use, and several precautions should be observed to minimize risk.

- Evaluate cardiovascular status; avoid in patients with known QT prolongation. - Monitor for signs of extrapyramidal reactions, especially in early treatment. - Assess liver and renal function periodically during long‑term therapy. - Use caution in patients with a history of seizures or neuroleptic malignant syndrome. - Discuss potential prolactin elevation with women of childbearing age and consider fertility implications. - Avoid abrupt discontinuation; taper under medical guidance to prevent withdrawal phenomena. - Consider pregnancy and lactation status; use only if benefits outweigh potential risks.

Haloperidol decanoate can interact with other medications, altering its efficacy or safety profile. Recognizing key interactions helps clinicians manage therapy appropriately.

Avoid: - Concurrent use with other dopamine antagonists or high‑potency antipsychotics, which may increase extrapyramidal risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels. - QT‑prolonging agents such as certain antiarrhythmics, macrolide antibiotics, or antipsychotics.

Use with caution: - CYP3A4 inducers (e.g., carbamazepine, rifampin) that may reduce drug exposure. - CNS depressants, including benzodiazepines or opioids, which can enhance sedation. - Anticholinergic drugs that may mask extrapyramidal symptoms.